Kadmon doses first patient in Phase 2 trial of KD025 to treat chronic graft-versus-host disease
Kadmon Holdings has dosed the first patient under a Phase 2 clinical trial of KD025, which is its rho-associated coiled-coil kinase 2 (ROCK2) inhibitor to treat chronic graft-versus-host disease (cGVHD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Pharmaceuticals